Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 491

1.

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.

Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honoré S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL.

Clin Cancer Res. 2020 Jan 22. doi: 10.1158/1078-0432.CCR-19-2109. [Epub ahead of print]

PMID:
31969329
2.

Diffuse Glioneuronal tumour with Oligodendroglioma-like features and Nuclear Clusters (DGONC) - a molecularly-defined glioneuronal CNS tumour class displaying recurrent monosomy 14.

Deng MY, Sill M, Sturm D, Stichel D, Witt H, Ecker J, Wittmann A, Schittenhelm J, Ebinger M, Schuhmann MU, Figarella-Branger D, Aronica E, Staszewski O, Preusser M, Haberler C, Lauten M, Schüller U, Hartmann C, Snuderl M, Dunham C, Jabado N, Wesseling P, Deckert M, Keyvani K, Gottardo N, Giangaspero F, von Hoff K, Ellison DW, Pietsch T, Herold Mende C, Milde T, Witt O, Kool M, Korshunov A, Wick W, von Deimling A, Pfister SM, Jones DTW, Sahm F.

Neuropathol Appl Neurobiol. 2019 Dec 23. doi: 10.1111/nan.12590. [Epub ahead of print]

PMID:
31867747
3.

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network .

Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.

PMID:
31832685
4.

The molecular landscape of ETMR at diagnosis and relapse.

Lambo S, Gröbner SN, Rausch T, Waszak SM, Schmidt C, Gorthi A, Romero JC, Mauermann M, Brabetz S, Krausert S, Buchhalter I, Koster J, Zwijnenburg DA, Sill M, Hübner JM, Mack N, Schwalm B, Ryzhova M, Hovestadt V, Papillon-Cavanagh S, Chan JA, Landgraf P, Ho B, Milde T, Witt O, Ecker J, Sahm F, Sumerauer D, Ellison DW, Orr BA, Darabi A, Haberler C, Figarella-Branger D, Wesseling P, Schittenhelm J, Remke M, Taylor MD, Gil-da-Costa MJ, Łastowska M, Grajkowska W, Hasselblatt M, Hauser P, Pietsch T, Uro-Coste E, Bourdeaut F, Masliah-Planchon J, Rigau V, Alexandrescu S, Wolf S, Li XN, Schüller U, Snuderl M, Karajannis MA, Giangaspero F, Jabado N, von Deimling A, Jones DTW, Korbel JO, von Hoff K, Lichter P, Huang A, Bishop AJR, Pfister SM, Korshunov A, Kool M.

Nature. 2019 Dec;576(7786):274-280. doi: 10.1038/s41586-019-1815-x. Epub 2019 Dec 4.

PMID:
31802000
5.

EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma.

Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Stücklin ASG, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P.

Lancet Oncol. 2019 Dec;20(12):e715-e728. doi: 10.1016/S1470-2045(19)30669-2. Review.

PMID:
31797797
6.

An Epidemiology Report for Primary Central Nervous System Tumors in Adolescents and Young Adults: a nationwide population-based study in France, 2008-2013.

Ng S, Zouaoui S, Bessaoud F, Rigau V, Roux A, Darlix A, Bauchet F, Mathieu-Daudé H, Trétarre B, Figarella-Branger D, Pallud J, Frappaz D, Roujeau T, Bauchet L.

Neuro Oncol. 2019 Dec 4. pii: noz227. doi: 10.1093/neuonc/noz227. [Epub ahead of print]

PMID:
31796950
7.

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.

Grandin N, Pereira B, Cohen C, Billard P, Dehais C, Carpentier C, Idbaih A, Bielle F, Ducray F, Figarella-Branger D, Delattre JY, Sanson M, Lomonte P, Poncet D, Verrelle P, Charbonneau M; POLA network.

Acta Neuropathol Commun. 2019 Nov 9;7(1):175. doi: 10.1186/s40478-019-0833-0.

8.

The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population.

Gareton A, Tauziède-Espariat A, Dangouloff-Ros V, Roux A, Saffroy R, Castel D, Kergrohen T, Fina F, Figarella-Branger D, Pagès M, Bourdeaut F, Doz F, Puget S, Dufour C, Lechapt E, Chrétien F, Grill J, Varlet P.

Acta Neuropathol. 2019 Nov 1. doi: 10.1007/s00401-019-02088-8. [Epub ahead of print]

PMID:
31677015
9.

Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.

Pouget C, Hergalant S, Lardenois E, Lacomme S, Houlgatte R, Carpentier C, Dehais C, Rech F, Taillandier L, Sanson M, Appay R, Colin C, Figarella-Branger D, Battaglia-Hsu SF, Gauchotte G.

Brain Pathol. 2019 Sep 27. doi: 10.1111/bpa.12788. [Epub ahead of print]

PMID:
31561286
10.

Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas.

Surun A, Varlet P, Brugières L, Lacour B, Faure-Conter C, Leblond P, Bertozzi-Salomon AI, Berger C, André N, Sariban E, Raimbault S, Prieur F, Desseigne F, Zattara H, Guimbaud R, Polivka M, Delisle MB, Vasiljevic A, Maurage CA, Figarella-Branger D, Coulet F, Guerrini-Rousseau L, Alapetite C, Dufour C, Colas C, Doz F, Bourdeaut F.

Neuro Oncol. 2020 Jan 11;22(1):128-138. doi: 10.1093/neuonc/noz154.

PMID:
31504825
11.

Glycolipids Recognized by A2B5 Antibody Promote Proliferation, Migration, and Clonogenicity in Glioblastoma Cells.

Baeza-Kallee N, Bergès R, Soubéran A, Colin C, Denicolaï E, Appay R, Tchoghandjian A, Figarella-Branger D.

Cancers (Basel). 2019 Aug 28;11(9). pii: E1267. doi: 10.3390/cancers11091267.

12.

WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.

Varlet P, Le Teuff G, Le Deley MC, Giangaspero F, Haberler C, Jacques TS, Figarella-Branger D, Pietsch T, Andreiuolo F, Deroulers C, Jaspan T, Jones C, Grill J.

Neuro Oncol. 2020 Jan 11;22(1):116-127. doi: 10.1093/neuonc/noz142.

13.

Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1.

Sievers P, Appay R, Schrimpf D, Stichel D, Reuss DE, Wefers AK, Reinhardt A, Coras R, Ruf VC, Schmid S, de Stricker K, Boldt HB, Kristensen BW, Petersen JK, Ulhøi BP, Gardberg M, Aronica E, Hasselblatt M, Brück W, Bielle F, Mokhtari K, Lhermitte B, Wick W, Herold-Mende C, Hänggi D, Brandner S, Giangaspero F, Capper D, Rushing E, Wesseling P, Pfister SM, Figarella-Branger D, von Deimling A, Sahm F, Jones DTW.

Acta Neuropathol. 2019 Sep;138(3):497-504. doi: 10.1007/s00401-019-02038-4. Epub 2019 Jun 27.

PMID:
31250151
14.

High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma.

Dardaud LM, Bris C, Desquiret-Dumas V, Boisselier B, Tabouret E, Mokhtari K, Figarella-Branger D, Rousseau A, Procaccio V.

Neuro Oncol. 2019 Apr 26. pii: noz072. doi: 10.1093/neuonc/noz072. [Epub ahead of print] No abstract available.

PMID:
31095694
15.

Can histologically normal epileptogenic zone share common electrophysiological phenotypes with focal cortical dysplasia? SEEG-based study in MRI-negative epileptic patients.

Lagarde S, Scholly J, Popa I, Valenti-Hirsch MP, Trebuchon A, McGonigal A, Milh M, Staack AM, Lannes B, Lhermitte B, Proust F, Benmekhbi M, Scavarda D, Carron R, Figarella-Branger D, Hirsch E, Bartolomei F.

J Neurol. 2019 Aug;266(8):1907-1918. doi: 10.1007/s00415-019-09339-4. Epub 2019 May 4.

PMID:
31055634
16.

cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates.

Louis DN, Ellison DW, Brat DJ, Aldape K, Capper D, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, von Deimling A, Wesseling P.

Brain Pathol. 2019 Jul;29(4):469-472. doi: 10.1111/bpa.12732. Epub 2019 May 22. Review.

PMID:
31038238
17.

The French glioblastoma biobank (FGB): a national clinicobiological database.

Clavreul A, Soulard G, Lemée JM, Rigot M, Fabbro-Peray P, Bauchet L, Figarella-Branger D, Menei P; FGB network.

J Transl Med. 2019 Apr 23;17(1):133. doi: 10.1186/s12967-019-1859-6.

18.

Inhibitor of Apoptosis Proteins Determines Glioblastoma Stem-Like Cell Fate in an Oxygen-Dependent Manner.

Soubéran A, Cappaï J, Chocry M, Nuccio C, Raujol J, Colin C, Lafitte D, Kovacic H, Quillien V, Baeza-Kallee N, Rougon G, Figarella-Branger D, Tchoghandjian A.

Stem Cells. 2019 Jun;37(6):731-742. doi: 10.1002/stem.2997. Epub 2019 Mar 28.

PMID:
30920104
19.

Correction to: Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.

Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D.

J Neurooncol. 2019 May;142(3):521. doi: 10.1007/s11060-019-03141-y.

PMID:
30859482
20.

Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear.

Vogels R, Macagno N, Griewank K, Groenen P, Verdijk M, Fonville J, Kusters B; French CNS SFT/HPC Consortium; Dutch CNS SFT/HPC Consortium, Figarella-Branger D, Wesseling P, Bouvier C, Flucke U.

Acta Neuropathol. 2019 Apr;137(4):679-682. doi: 10.1007/s00401-019-01968-3. Epub 2019 Feb 2. No abstract available.

PMID:
30761420
21.

Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.

Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D.

J Neurooncol. 2019 May;142(3):511-520. doi: 10.1007/s11060-019-03122-1. Epub 2019 Feb 11. Erratum in: J Neurooncol. 2019 Mar 11;:.

PMID:
30756272
22.

Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.

Autran D, Barrie M, Matta M, Monserrat C, Campello C, Petrirena G, Boucard C, Padovani L, Loundou A, Appay R, Graillon T, Dufour H, Figarella-Branger D, Chinot O, Tabouret E.

Anticancer Res. 2019 Feb;39(2):1035-1041. doi: 10.21873/anticanres.13210.

PMID:
30711992
23.

Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.

Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, Mathieu-Daude H, Bessaoud F, Bauchet F, Riondel A, Sorbets E, Charissoux M, Amelot A, Mandonnet E, Figarella-Branger D, Duffau H, Tretarre B, Taillandier L, Bauchet L.

J Neurooncol. 2019 Mar;142(1):91-101. doi: 10.1007/s11060-018-03065-z. Epub 2018 Dec 6.

24.

ETMR-like infantile cerebellar embryonal tumors in the extended morphologic spectrum of DICER1-related tumors.

Uro-Coste E, Masliah-Planchon J, Siegfried A, Blanluet M, Lambo S, Kool M, Roujeau T, Boetto S, Palenzuela G, Bertozzi AI, Gambart M, Coupier I, Oliver-Petit I, Golmard L, Julia S, Savagner F, Mohand-Oumoussa B, Tauziede-Espariat A, Delisle MB, Figarella-Branger D, Bourdeaut F, Rigau V.

Acta Neuropathol. 2019 Jan;137(1):175-177. doi: 10.1007/s00401-018-1935-7. Epub 2018 Nov 16. No abstract available.

PMID:
30446821
25.

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.

Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC.

Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1.

26.

Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population.

Muracciole X, El-Amine W, Tabouret E, Boucekine M, Barlier A, Petrirena G, Harivony T, Solignac L, Chinot OL, Macagno N, Figarella-Branger D, Padovani L.

Front Oncol. 2018 Oct 4;8:426. doi: 10.3389/fonc.2018.00426. eCollection 2018.

27.

Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma.

Berges R, Denicolai E, Tchoghandjian A, Baeza-Kallee N, Honore S, Figarella-Branger D, Braguer D.

Cell Death Dis. 2018 Sep 24;9(10):984. doi: 10.1038/s41419-018-1018-7.

28.

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network.

Acta Neuropathol Commun. 2018 Sep 7;6(1):89. doi: 10.1186/s40478-018-0594-1.

29.

Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group.

Rutkowski S, Modena P, Williamson D, Kerl K, Nysom K, Pizer B, Bartels U, Puget S, Doz F, Michalski A, von Hoff K, Chevignard M, Avula S, Murray MJ, Schönberger S, Czech T, Schouten-van Meeteren AYN, Kordes U, Kramm CM, van Vuurden DG, Hulleman E, Janssens GO, Solanki GA, van Veelen MC, Thomale U, Schuhmann MU, Jones C, Giangaspero F, Figarella-Branger D, Pietsch T, Clifford SC, Pfister SM, Van Gool SW.

Lancet Oncol. 2018 Aug;19(8):e419-e428. doi: 10.1016/S1470-2045(18)30364-4. Review.

PMID:
30102236
30.

Otx2 promotes granule cell precursor proliferation and Shh-dependent medulloblastoma maintenance in vivo.

El Nagar S, Chakroun A, Le Greneur C, Figarella-Branger D, Di Meglio T, Lamonerie T, Billon N.

Oncogenesis. 2018 Aug 13;7(8):60. doi: 10.1038/s41389-018-0070-6.

31.

Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.

Rosenberg S, Ducray F, Alentorn A, Dehais C, Elarouci N, Kamoun A, Marie Y, Tanguy ML, De Reynies A, Mokhtari K, Figarella-Branger D, Delattre JY, Idbaih A; POLA Network.

Oncologist. 2018 Dec;23(12):1500-1510. doi: 10.1634/theoncologist.2017-0495. Epub 2018 Jul 17.

32.

A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.

Rosenberg S, Simeonova I, Bielle F, Verreault M, Bance B, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella-Branger D, Aubriot-Lorton MH, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Sharif A, Mokhtari K, Pagnotta SM, Iavarone A, Lasorella A, Huillard E, Sanson M.

Nat Commun. 2018 Jun 18;9(1):2371. doi: 10.1038/s41467-018-04622-w.

33.

Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas.

Appay R, Fina F, Macagno N, Padovani L, Colin C, Barets D, Ordioni J, Scavarda D, Giangaspero F, Badiali M, Korshunov A, M Pfister S, T W Jones D, Figarella-Branger D.

Mod Pathol. 2018 Oct;31(10):1490-1501. doi: 10.1038/s41379-018-0050-6. Epub 2018 May 25.

34.

Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system.

Rochette C, Baumstarck K, Canoni-Zattara H, Abdullah AE, Figarella-Branger D, Pertuit M, Barlier A, Castinetti F, Pacak K, Metellus P, Taïeb D.

J Psychosoc Oncol. 2018 Sep-Oct;36(5):624-634. doi: 10.1080/07347332.2018.1450320. Epub 2018 May 15.

PMID:
29764331
35.

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.

Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, Brouwer-Visser J, Giangaspero F, Haberler C, Pietsch T, Jacques TS, Figarella-Branger D, Rodriguez D, Morgan PS, Raman P, Waanders AJ, Resnick AC, Massimino M, Garrè ML, Smith H, Capper D, Pfister SM, Würdinger T, Tam R, Garcia J, Thakur MD, Vassal G, Grill J, Jaspan T, Varlet P, Jones C.

Cancer Cell. 2018 May 14;33(5):829-842.e5. doi: 10.1016/j.ccell.2018.04.004.

36.

EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity.

Siegfried A, Rousseau A, Maurage CA, Pericart S, Nicaise Y, Escudie F, Grand D, Delrieu A, Gomez-Brouchet A, Le Guellec S, Franchet C, Boetto S, Vinchon M, Sol JC, Roux FE, Rigau V, Bertozzi AI, Jones DTW, Figarella-Branger D, Uro-Coste E.

Brain Pathol. 2019 Jan;29(1):53-62. doi: 10.1111/bpa.12619. Epub 2018 Jul 13.

PMID:
29679497
37.

Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients.

Macagno N, Vogels R, Appay R, Colin C, Mokhtari K; French CNS SFT/HPC Consortium; Dutch CNS SFT/HPC Consortium, Küsters B, Wesseling P, Figarella-Branger D, Flucke U, Bouvier C.

Brain Pathol. 2019 Jan;29(1):18-27. doi: 10.1111/bpa.12613. Epub 2018 May 7.

PMID:
29600523
38.

IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA Network.

Neuro Oncol. 2018 Apr 9;20(5):716-718. doi: 10.1093/neuonc/noy014. No abstract available.

39.

Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool.

Tsvetkov PO, Tabouret E, Roman AY, Romain S, Bequet C, Ishimbaeva O, Honoré S, Figarella-Branger D, Chinot O, Devred F.

Oncotarget. 2018 Jan 25;9(10):9391-9399. doi: 10.18632/oncotarget.24317. eCollection 2018 Feb 6.

40.

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.

Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P.

Acta Neuropathol. 2018 Apr;135(4):639-642. doi: 10.1007/s00401-018-1826-y. Epub 2018 Mar 1. No abstract available.

PMID:
29497819
41.

Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.

Bruno A, Labreche K, Daniau M, Boisselier B, Gauchotte G, Royer-Perron L, Rahimian A, Lemoine F, de la Grange P, Guégan J, Bielle F, Polivka M, Adam C, Meyronet D, Figarella-Branger D, Villa C, Chrétien F, Eimer S, Davi F, Rousseau A, Houillier C, Soussain C, Mokhtari K, Hoang-Xuan K, Alentorn A.

Neuro Oncol. 2018 Jul 5;20(8):1092-1100. doi: 10.1093/neuonc/noy019.

42.

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC).

Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M.

Acta Neuropathol. 2018 Mar;135(3):481-484. doi: 10.1007/s00401-018-1808-0. Epub 2018 Jan 25. No abstract available.

PMID:
29372318
43.

De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Peyre M, Gauchotte G, Giry M, Froehlich S, Pallud J, Graillon T, Bielle F, Cazals-Hatem D, Varlet P, Figarella-Branger D, Loiseau H, Kalamarides M.

Neuro Oncol. 2018 Jul 5;20(8):1113-1121. doi: 10.1093/neuonc/nox231.

44.

Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report.

Berland M, Padovani L, Rome A, Pech-Gourg G, Figarella-Branger D, André N.

Front Pharmacol. 2017 Nov 1;8:792. doi: 10.3389/fphar.2017.00792. eCollection 2017.

45.

Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.

Bielle F, Di Stefano AL, Meyronet D, Picca A, Villa C, Bernier M, Schmitt Y, Giry M, Rousseau A, Figarella-Branger D, Maurage CA, Uro-Coste E, Lasorella A, Iavarone A, Sanson M, Mokhtari K.

Brain Pathol. 2018 Sep;28(5):674-683. doi: 10.1111/bpa.12563. Epub 2017 Nov 21.

PMID:
28976058
46.

DOCK4 promotes loss of proliferation in glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster expression.

Debruyne DN, Turchi L, Burel-Vandenbos F, Fareh M, Almairac F, Virolle V, Figarella-Branger D, Baeza-Kallee N, Lagadec P, Kubiniek V, Paquis P, Fontaine D, Junier MP, Chneiweiss H, Virolle T.

Oncogene. 2018 Jan 11;37(2):241-254. doi: 10.1038/onc.2017.323. Epub 2017 Sep 18.

PMID:
28925399
47.

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro.

Graillon T, Romano D, Defilles C, Lisbonis C, Saveanu A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A.

Oncotarget. 2017 Jul 24;8(33):55361-55373. doi: 10.18632/oncotarget.19517. eCollection 2017 Aug 15.

48.

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191.

49.

HGNET-BCOR Tumors of the Cerebellum: Clinicopathologic and Molecular Characterization of 3 Cases.

Appay R, Macagno N, Padovani L, Korshunov A, Kool M, André N, Scavarda D, Pietsch T, Figarella-Branger D.

Am J Surg Pathol. 2017 Sep;41(9):1254-1260. doi: 10.1097/PAS.0000000000000866.

PMID:
28704208
50.

Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis.

Tauziede-Espariat A, Parfait B, Besnard A, Lacombe J, Pallud J, Tazi S, Puget S, Lot G, Terris B, Cohen J, Vidaud M, Figarella-Branger D, Monnien F, Polivka M, Adle-Biassette H, Varlet P.

Brain Pathol. 2018 Jul;28(4):466-474. doi: 10.1111/bpa.12524. Epub 2017 Jun 12.

PMID:
28474749

Supplemental Content

Loading ...
Support Center